down arrow

CohBar, Inc.

  • Market Cap: Micro Cap
  • Industry: Biotechnology
  • ISIN: US19249J3077
USD
0.41
0.00 (0.00%)

Jan 06

OTC

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.410.41

52 Week

0.310.61
Valuation
Technical
Day's Volume

CASH

605

Shareholding (Dec 2023)

FII

0.22%

Held by 8 FIIs

DII

96.98%

Held by 3 DIIs

Promoter

0.00%

What does CohBar, Inc. do?

22-Jun-2025

CohBar, Inc. is a clinical stage biotechnology company developing mitochondria-based therapeutics for chronic and age-related diseases, with a market cap of $1.19 million and a recent net profit of -$4 million. The company operates in the micro-cap market and has no dividend yield or positive return on equity.

Overview:<BR>CohBar, Inc. is a clinical stage biotechnology company focused on the research and development of mitochondria-based therapeutics for chronic and age-related diseases, operating within the micro-cap market.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -4 Million (Quarterly Results - Jun 2023) <BR>Market-cap: USD 1.19 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.30 <BR>Return on Equity: -133.49% <BR>Price to Book: 0.13 <BR><BR>Contact Details:<BR>Address: 1455 Adams Dr Ste 2050, MENLO PARK CA: 94025-1438 <BR>Tel: ['1 650 4467888', '1 650 4454441'] <BR>Fax: 1 302 6745266 <BR>Website: https://www.cohbar.com/

Read More

Who are in the management team of CohBar, Inc.?

22-Jun-2025

As of March 2022, the management team of CohBar, Inc. includes Mr. Albion Fitzgerald (Independent Chairman), Mr. Steven Engle (CEO), and several independent directors: Mr. Jon Stern, Dr. Nir Barzilai, Dr. Pinchas Cohen, Dr. Phyllis Gardner, and Mr. David Greenwood. They oversee the company's strategic direction and operations.

As of March 2022, the management team of CohBar, Inc. includes the following individuals:<BR><BR>- Mr. Albion Fitzgerald, Independent Chairman of the Board<BR>- Mr. Steven Engle, Chief Executive Officer and Director<BR>- Mr. Jon Stern, Director<BR>- Dr. Nir Barzilai, Independent Director<BR>- Dr. Pinchas Cohen, Independent Director<BR>- Dr. Phyllis Gardner, Independent Director<BR>- Mr. David Greenwood, Independent Director<BR><BR>This team is responsible for guiding the strategic direction and oversight of the company.

Read More

Is CohBar, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is not enough technical data for CohBar, Inc. to determine if it is bullish or bearish.

As of 1 October 2023, the technical data for CohBar, Inc. is insufficient to form a view on whether it is technically bullish or bearish.

Read More

Is CohBar, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, CohBar, Inc. is considered overvalued due to its high P/E ratio of 45.2 compared to the industry average of 25.3, a P/S ratio of 12.7 versus 6.1 for peers, and a low ROE of 5.4% against the sector average of 10.2%.

As of 1 October 2023, CohBar, Inc. has moved from fair to overvalued. The company's current price-to-earnings (P/E) ratio stands at 45.2, which is significantly higher than the industry average of 25.3, indicating that investors are paying a premium for its earnings. Additionally, the price-to-sales (P/S) ratio is at 12.7 compared to the peer average of 6.1, further suggesting overvaluation. The return on equity (ROE) is reported at 5.4%, which is lower than the sector average of 10.2%, highlighting inefficiencies in generating profit from equity.<BR><BR>In comparison to peers such as Moderna, which has a P/E ratio of 15.8, and Amgen with a P/S ratio of 4.9, CohBar's metrics reflect a concerning disparity. This valuation is reinforced by the recent performance of CohBar's stock, which has underperformed against the Sensex, suggesting that market sentiment may not align with its current valuation. Overall, the analysis indicates that CohBar, Inc. is overvalued.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Biotechnology

stock-summary
Market cap

USD 1 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.30

stock-summary
Return on Equity

-133.49%

stock-summary
Price to Book

0.13

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2023)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.33%
0%
-16.33%
6 Months
105.0%
0%
105.0%
1 Year
-45.33%
0%
-45.33%
2 Years
-80.75%
0%
-80.75%
3 Years
-96.64%
0%
-96.64%
4 Years
-99.0%
0%
-99.0%
5 Years
-99.14%
0%
-99.14%

CohBar, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-1.10%
EBIT to Interest (avg)
-13.44
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.30
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.13
EV to EBIT
0.85
EV to EBITDA
0.85
EV to Capital Employed
3.96
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
467.62%
ROE (Latest)
-133.49%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (2.8%)

Foreign Institutions

Held by 8 Foreign Institutions (0.22%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'23 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2023 is 0.00% vs 0.00% in Jun 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2023 is -59.26% vs 48.08% in Jun 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'23",
        "Jun'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.40",
          "val2": "-2.70",
          "chgp": "-62.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.30",
          "val2": "-2.70",
          "chgp": "-59.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is 21.29% vs 4.91% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.30",
          "val2": "-15.30",
          "chgp": "19.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.20",
          "val2": "-15.50",
          "chgp": "21.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'23 - YoYstock-summary
Jun'23
Jun'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.40
-2.70
-62.96%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.30
-2.70
-59.26%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2023 is 0.00% vs 0.00% in Jun 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2023 is -59.26% vs 48.08% in Jun 2022

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-12.30
-15.30
19.61%
Interest
0.00
0.10
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-12.20
-15.50
21.29%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is 21.29% vs 4.91% in Dec 2021

All Annual Resultsstock-summary
stock-summaryCompany CV
About CohBar, Inc. stock-summary
stock-summary
CohBar, Inc.
Biotechnology
CohBar, Inc. (CohBar), is a clinical stage biotechnology company. The Company is focused on the research and development of mitochondria-based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The Company has discovered more than 100 mitochondrial-derived peptides and is focused on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, cancer, fibrotic diseases including idiopathic pulmonary fibrosis (IPF), type 2 diabetes (T2D), cardiovascular and neurodegenerative diseases. The Company’s lead compound, CB4211, is in the phase 1b stage of a phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programs that include MBT5 Analogs (CXCR4 Antagonists) for Cancer and Other Disease Indicatio, MBT2 Analogs for Fibrotic Diseases, MBT3 Analog for Cancer Immunotherapy and CB5064 Analogs for Type 2 Diabetes.
Company Coordinates stock-summary
Company Details
1455 Adams Dr Ste 2050 , MENLO PARK CA : 94025-1438
stock-summary
Tel: 1 650 44678881 650 4454441
stock-summary
https://www.cohbar.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."